

Treatment Outcomes of Tuberculosis Patients at Bale Robe Hospital Oromia Regional State, Ethiopia: A Five Year Retrospective Study

Erdaw Tachbele^{1*}, Biruhalem Taye², Begna Tulu³ and Gobena Ameni^{3*}

¹Department of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Ethiopia

²Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia

³Microbiology, Immunology and Parasitology Department, Bahir Dar University, Ethiopia

*Corresponding author: Erdaw Tachbele, P.O. Box 11240, Addis Ababa, Ethiopia, Tel: +251911642880; E-mail: Erdaw.tachbele@aau.edu.et

Received date: December 16, 2016; Accepted date: March 15, 2017; Published date: March 23, 2017

Copyright: © 2017 Tachbele E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract

Objective: Monitoring of tuberculosis treatment outcome is scarcely done in Ethiopia. This study investigated the outcomes of tuberculosis treatment at Bale Robe Hospital in Oromia, Ethiopia.

Methods: A retrospective analysis of the profile and treatment outcome of all tuberculosis patients registered from September, 2007 to August, 2012 at tuberculosis Clinic was conducted. Patients' socio-demographic, clinical, laboratory and treatment outcomes were extracted from registration document. Bivariate and multivariate logistic regression was used to determine treatment outcomes predictor variables.

Results: We analyzed treatment outcomes of 916 tuberculosis patients, of which 544 (59.6 %) were males. Of these 180 (19.7%) were cured, 536 (58.5%) were found completed their treatment, while 82 (9%) were died, in addition, 55 (6.0%) and 54 (5.9%) were defaulters and transferred out respectively. Overall, 716 (78.2%) had a successful and 200 (21.8%) a poor treatment outcome. Being female (AOR 1.23, P=0.05), HIV positive (0.48, P<0.001) and new TB patients (AOR 2.17, P=0.002) were significantly associated with treatment outcome. Patients aged ≤ 14 had significantly high treatment success rate (AOR 4.99, P=0.003) followed by 35-44 years (AOR 3.5, P=0.009) and 25-34 years (AOR 2.52, P=0.029). Tuberculosis patients with HIV co-infection (AOR 4.32, P=<0.001), smear negative pulmonary tuberculosis (AOR 2.00, P=0.05) and age ≥ 65 years (AOR 5.50, P=0.03) were more likely to experience death than their counter parts.

Conclusion: The treatment success rate of 78.2% tuberculosis patients was fairly good. However, a high proportion of patients (9%) death and 22.2% of HIV prevalence among TB patients is a serious public health concern that needs to be addressed urgently in the area.

Keywords: Treatment outcomes; Tuberculosis; DOTS; Bale robe; Ethiopia

Abbreviations: AFB: Acid Fast Bacilli, AOR: Adjusted Odds Ratio, CDR: Case Detection Rate, DOTS: Directly Observed Treatment, Short Course, GTB: Global Tuberculosis Programme, HBCs: High-Burden Countries, HIV: Human Immunodeficiency Virus, MDR: Multiple Drug Resistance, NTLCP: National Tuberculosis and Leprosy Control Program, TSR: Treatment Success Rate

Introduction and Background

Despite great effort is exerted globally to combat tuberculosis (TB), still it remains the major cause of mortality worldwide and accounts for 25% of all avoidable deaths in developing countries and 2.5% of the world diseases Burdon [1].

The WHO 2013 report indicated that Ethiopia stands eighth among the world's 22 high tuberculosis Burdon countries [2]. Tuberculosis is the leading cause of morbidity, the third cause of hospital admission and the second cause of death in Ethiopia [3].

Without treatment, TB mortality rates are high. Natural history of disease studies showed that around 70% of sputum smear positive HIV-negative pulmonary TB cases died within 10 years, and 20% of culture positive (but smear negative) cases died within 10 years [4].

Since 1990 the WHO Global Tuberculosis Programme (GTB) has promoted the revision of national tuberculosis programmes to strengthen the focus on directly observed treatment, short-course (DOTS) and close monitoring of treatment outcomes. Patients treated by DOTS at the start of therapy had a significantly higher cure rate and decreased tuberculosis-related mortality compared with patients treated by self-administered therapy [5]. The implementation of DOTS and its subsequent surveillance system of treatment outcomes revealed 82% global treatment success rate in DOTs areas in comparison to only 67% in non-DOTs areas [6].

Routine recording and reporting of the numbers of TB cases diagnosed and treated by National Tuberculosis Programmes (NTPs) and monitoring of treatment outcomes was one of the five components of the global TB strategy (DOTS) launched by WHO in the mid-1990s and it remains a core element of its successor, the Stop TB Strategy [2], with set targets of 84% case detection rate (CDR) and 87% treatment success rate (TSR) by 2015. Between 1995 and 2012, 56 million people

were successfully treated for TB in countries that had adopted the DOTS/Stop TB Strategy which saved approximately 22 million lives [2]. In 2011, the global treatment success rate was 87% among all new TB cases, except the European Region where the treatment success rate ranges from 65% for new smear positive cases to 72% for new smear negative cases [2].

In Ethiopia, Directly Observed Treatment, Short Course (DOTS), was started in 1992. Since then, the DOTS programme has been successively scaled up in the country with a 100% geographical coverage, and 95% health facility coverage [3]. The implementation of DOTS in Ethiopia has been associated with high rate of successful treatment outcome and reduced development of drug resistance [7]. According to WHO report, in 2011 Ethiopia reported treatment success rate of 90% for new smear positive, 87% for smear negative/extra pulmonary, and 78 % for retreatment cases with case detection rate of 64% [2]. In reference to the updated global TB plan (2011-2015) with a set targets of 87% treatment success rate and 84 case detection rate, Ethiopia achieved the treatment success rate but needs to work hard to reach the global plan of case detection rate.

Monitoring the outcome of treatment by cohort analysis of tuberculosis patients is essential in order to evaluate the effectiveness of DOTS program and serves as a proxy of quality of TB treatment in a health care system [7,8]. In addition to this, understanding the determinant factors of unsuccessful treatment outcomes is crucial to improve the TB control system.

To this end, very few studies have reported treatment outcomes of DOTS in different parts of Ethiopia from 2005 to 2013 [7-18]. The studies conducted so far in different parts of the country (Southern region, Addis Ababa, Gambella and Northern region) documented different rate of treatment success rates ranging from 29.5% in Gondar, North west Ethiopia [15], to 89.2% in Tigray, Northern Ethiopia [17]. According to these studies, being male, older age, place of treatment, smear negative pulmonary TB, HIV positive, smear positive pulmonary TB at 2nd month follow up and retreatment cases were found to be the determinant factors of unsuccessful treatment outcomes [7,8,11,13,15-20].

Although Ethiopia has fully implemented DOTS program across the whole nation, information on epidemiological cohort analysis of TB treatment outcomes, especially in Oromia National Regional State is severely lacking. Therefore, this study was designed to investigate the treatment outcomes of TB patients and assess the association of demographic and clinical factors with treatment success of patients enrolled in Directly Observed Treatment Short Course (DOTS) program in Bale Robe Hospital Oromia, Ethiopia over the course of five consecutive years (From Sep 2007 to Aug 2012).

Methods

Study setting

Bale Robe is a regional hospital serving the population of Robe town and that of South West Ethiopia. The total population served by the hospital is about 569,707. In the hospital a Directly Observed Therapy; Short-Course (DOTS) clinic is operating under the National Tuberculosis and Leprosy Control Program (NTLCP) of Ethiopia, under which the diagnosis of pulmonary TB is followed by examination of three sputum smears by Zihel-Nielsen staining method for acid fast bacilli (AFB). Chest radiographs and pathological investigations are also used to support the diagnosis. Patients

diagnosed with tuberculosis are referred to the DOTS clinic where they are registered and treated according to the NTLCP guideline [3,21].

Study design and data collection

Institution based retrospective analysis of the profile and treatment outcome of all tuberculosis patients (cohort) registered from September, 2007 to August, 2012 at DOTS Clinic was conducted. The registration documents reviewed contain patient's age, sex, residence, weight, Acid Fast Bacilli smear result at base line, HIV status, 2nd 5th and 7th months follow up AFB smear result and weight, treatment regimen, treatment started and completed dates and treatment outcomes. The required information was extracted from TB treatment log books (registration document) using structured data reviewing formats by the investigators.

Dependent and independent variables

Dependent variables: Treatment success (cured or completed treatment) and Unsuccessful treatment (either treatment failure, defaulter, died, or transferred out).

Independent variables for treatment outcomes were: TB Patients' age, sex, weight, residence HIV status, type of TB, patient category at the start of treatment and AFB smear-positive at baseline, 2 month, 5 month and 7 months.

Data management and statistical analysis

Data were entered, cleared and analyzed using the statistical package SPSS for windows, version 20. For categorical data, we used proportions with 95% confidence intervals, Odds ratio and Chi-square test to compare different groups. Multivariate analysis using logistic regression model was used to analyze the association between treatment outcome and potential predictor variables. P values of less than 0.05 were considered statistically significant.

Ethical consideration

Institutional ethical clearance was obtained from the Institutional Review Board (IRB) of Addis Ababa University and permission was received from Bale Robe Hospital to use the data. Informed consent from study participants was not required as the survey was based on retrospective data with no patient interaction and the report is part of standard public health practice. In order to ensure confidentiality of the information, names or identification numbers of TB patients were not included in the data sheet.

Results

Demographic and clinical characteristics of study participants

A total of 916 tuberculosis patients were registered for DOTs program at Bale Robe Hospital, Oromia, between September 2007 and August 2012. Of these, 544 (59.6 %) were males and 372 (40.4%) were females with the mean, standard deviation and median age of 28.84, 14.65 and 25 years, respectively. More than half (59.9 %) of the study participants were concentrated between the age group of 15-34 years, which is believed to be the productive segment of the society. With regard to their residence majority 623 (68%) live in urban area where as 293 (32%) reside in rural setting. Of the total study participants, 373

(40.7%), 305 (33.3%), and 238 (26%) were smear negative pulmonary tuberculosis, extra pulmonary tuberculosis, and smear positive pulmonary tuberculosis cases respectively. With regard to treatment categories, 808 (88.2%) of the patients were new cases, 86 (9.4%) were transferred in patients while 16 (1.6%) were relapse cases. HIV sero-status of 711 (77.6%) study participants was known, out of which 158 (22.2%) were found to be positive (Table 1).

Characteristics	Frequency(N)	Percentage (%)
Sex		
Male	544	59.6
Female	372	40.4
Residence		
Urban	623	68
Rural	293	32
Age Group		
≤14	101	11
15-24	296	32.3
25-34	253	27.6
35-44	124	13.5
45-54	64	7
55-64	39	4.3
≥65	39	4.3
Category of Patients		
New Cases	808	88.2
Transfer in	86	9.4
Relapse	15	1.6
Failure	5	0.5
Defaulter	1	0.1
Transferred out	1	0.1
Tuberculosis Type		
SPPTB	238	26
SNPTB	373	40.7
EPTB	305	33.3
HIV Status (N=711)		
HIV Positive	158	22.2

HIV Negative	553	77.8
Treatment Outcomes		
Cured	180	19.7
Treatment completed	536	58.5
Died	82	9
Failure	9	1
Defaulter	55	6
Transferred out	54	5.9
Total	916	100

Table 1: General characteristics of study participants (n=916), Bale Robe Hospital, 2007-2012, N=916, SPPTB= Smear positive pulmonary TB, SNPTB=Smear Negative Pulmonary TB, EPTB=Extra Pulmonary TB.

Acid fast staining follow up result of registered TB patients during treatment

From the total of 238 (26%) smear positive pulmonary tuberculosis patients, 199 (83.60%) had AFB staining laboratory result at the end of the 2nd month of treatment, out of which only 3 (1.5%) were AFB positive. At the end of 5th month of treatment 193 (81%) smear positive pulmonary tuberculosis patients had AFB result, out of which 4 (2.1%) were remained positive. At the end of the 7th month a total of 173 (72.70%) had AFB laboratory result, of which all of them were AFB negative.

Treatment outcomes

We examined treatment outcomes of 916 tuberculosis patients who were registered on DOTs program at the Bale Robe hospital during the study period. Out of which 180 (19.7%) were cured, 536 (58.5%) were found completed their treatment, while 82 (9%) were died, in addition, 55 (6.0%) and 54 (5.9%) were defaulters and transferred out respectively. Overall, 716 (78.2%) had a successful and 200 (21.8%) a poor treatment outcome. Of those with a poor treatment outcome, 82 (41%) patients died, 55 (27.5%) defaulted and 54 (27%) transferred out (Table 1).

The result in Table 2 indicates that as age of tuberculosis patients increased death rate of patients was increased from 4 (4%) to 19 (6.4%), 21 (8.3%) to 14 (11.3%), 10 (15.5%) to 7 (17.9) and 7 (17.9) in the age group of 0-14 years, 15-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years and 65 years, respectively. Whereas the age of tuberculosis patients increased, treatment success rate of patients decreased from 91 (90.1%) to 229 (77.4%) to 99 (79.8%), 50 (78.1%), to 25 (64.1%), and 26 (66.7%), respectively.

Characteristics	Treatment Outcomes					
	Treatment Success N (%)	Transferred out N (%)	Default N (%)	Death N (%)	Failure N (%)	Total
Sex						

Male	413 (75.9)	38 (7)	39 (7.2)	45 (8.3)	9 (1.7)	544 (100)
Female	303 (81.5)	16 (4.3)	16 (4.3)	37 (9.9)	0 (0)	372 (100)
Residence						
Urban	495 (79.5)	35 (5.6)	35 (5.6)	52 (8.3)	6 (1.0)	623 (100)
Rural	221 (75.4)	19 (6.5)	20 (6.8)	30 (10.2)	3 (1.0)	293 (100)
Age Groups(years)						
≤14	91 (90.1)	2 (2.0)	4 (4.0)	4 (4.0)	0 (0)	101 (100)
15-24	229 (77.4)	22 (7.4)	22 (7.4)	19 (6.4)	4 (1.4)	296 (100)
25-34	196 (77.5)	17 (6.7)	16 (6.3)	21 (8.3)	3 (1.2)	253 (100)
35-44	99 (79.8)	6 ((4.8)	5 (4.0)	14 (11.3)	0 (0)	124 (100)
45-54	50 (78.1)	3 (4.7)	1 (1.6)	10 (15.5)	0 (0)	64 (100)
55-64	25 (64.1)	2 (5.1)	4 (1.6)	7 (17.9)	1 (2.6)	39 (100)
≥65	26 (66.7)	2 (5.1)	4 (10.3)	7 (17.9)	1 (2.6)	39 (100)
Patient Category						
New	645 (79.8)	44 (5.4)	39 (4.8)	73 (9)	7 (0.9)	808 (100)
Relapse	10 (67.7)	3 (20)	0 (0)	2 (13.3)	0 (0)	15 (100)
Failure	3 (60)	1 (20)	0 (0)	1 (20)	0 (0)	5 (100)
Defaulter	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)
Transferred in	56 (65.1)	6 (7)	16 (18.6)	6 (7)	2 (2.3)	86 (100)
Transferred out	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)
Tuberculosis Type						
SPPTB	190 (79.8)	16 (6.7)	11 (4.6)	16 (6.7)	5 (2.1)	238 (100)
SNPTB	284 (76.1)	19 (5.1)	19 (5.1)	49 (13.1)	2 (0.5)	373 (100)
EPTB	242 (79.3)	19 (6.2)	25 (8.2)	17 (5.6)	2 (0.7)	305 (100)
HIV Status(N=711)						
HIV positive	106 (67.1)	10 (6.3)	10 (6.3)	31 (19.6)	1 (0.6)	158 (100)
HIV Negative	447 (80.8)	30 (5.4)	38 (6.9)	33 (6.0)	5 (0.9)	553 (100)
Year of Treatment						
2008	152 (78.4)	15 (7.7)	6 (3.1)	18 (9.3)	3 (15)	194 (100)
2009	156 (81.7)	5 (2.6)	18 (9.4)	12 (6.3)	0 (0.0)	191 (100)
2010	158 (79.4)	7 (3.5)	14 (7.0)	17 (8.5)	3 (1.5)	199 (100)
2011	144 (75.8)	12 (6.3)	16 (8.4)	15 (7.9)	3 (1.6)	190 (100)
2012	106 (78.2)	15 (10.6)	1 (0.7)	20 (14.1)	0 (0.0)	142 (100)

Table 2: Treatment outcomes by sex, residence, age group, patient category, TB type, HIV status, and year of treatment Bale Hospital, Oromia regional State, 2007-2012, N=916, SPPTB=Smear Positive Pulmonary TB, SNPTB=Smear Negative Pulmonary TB, EPTB=Extra Pulmonary TB, N=Number.

Table 3 indicated that as age of tuberculosis patients increased, increasing pattern from 35.6% in the age group of 0-14 years to 71.8% prevalence of smear negative pulmonary tuberculosis cases showed in the age group of 66-99 years, whereas prevalence of Extra-

pulmonary tuberculosis (EPTB) showed decreasing pattern from 57.4% in the age group of 0-14 years to 17.9 % in the age group of 65-99 years ($\chi^2=71.36$, p. value=0.00). In multi variate analysis, younger

ages (≤ 14 years) were more likely to develop EPTB than their older counter parts (AOR=8.81, CI=3.03-25.65) result not shown.

Variables	Type of Tuberculosis			Total number of TB patient's n (%)	X ² (P. value)
	SPPTB n (%)	SNPTB n (%)	EPTB n (%)		
Sex					
Male	141 (25.9)	233 (41.1)	180 (33.1)	544 (100)	0.044 (0.98)
Female	97 (26.1)	150 (40.3)	125 (33.6)	372 (100)	
Age Categories					
0-14	7 (6.9)	36 (35.6)	58 (57.4)	101 (100)	
15-24	102 (34.5)	102 (34.5)	92 (31.1)	296 (100)	71.36 (00)
25-34	76 (30.0)	95 (37.5)	82 (32.4)	253 (100)	
35-44	29 (23.4)	56 (45.2)	39 (31.5)	124 (100)	
45- 54	11 (17.2)	36 (56.2)	17 (26.6)	64 (100)	
55-64	9 (23.1)	20 (51.3)	10 (25.6)	39 (100)	
65-99	4 (10.3)	28 (71.8)	7 (17.9)	39 (100)	
TB patient categories					46.47 (00)
New	192 (23.8)	343 (42.5)	273 (33.8)	808 (100)	
Relapse	13 (86.7)	1 (6.7)	1 (6.7)	15 (100)	
Failure	4 (80)	1 (20.0)	0 (0.0)	5 (100)	
Default	1 (100)	0 (0.0)	0 (0.0)	1 (100)	
Transferred in	28 (32.6)	28 (32.6)	30 (34.9)	86 (100)	
Transferred out	0 (0.0)	0 (0.0)	1 (100)	1 (100)	
Total	238 (26.0)	373 (40.7)	305 (33.3)	916 (100)	

Table 3: Association of TB type with sex, Age category and TB patient categories, Bale Robe Hospital, Oromia, September, 2007-August, 2012, N=916SPPTB=Smear Positive Pulmonary TB, SNPTB=Smear Negative Pulmonary TB, EPTB=Extra Pulmonary TB, N=Number.

As shown in Table 4, female tuberculosis patients had significantly higher treatment success rate (81.5% versus 75.9%) than male (AOR=1.23, CI=1.10-1.75). In addition, patients in the age group of 0-14 years (AOR=4.99, CI=1.75-14.27), 25-34 years (AOR=2.52, CI=1.10-8.91) and 35-44 years (AOR=3.50, CI=1.37-8.91) had significantly higher treatment success rate compared to the other age

groups. With regard to patient category at the start of treatment, new TB patients had significantly higher treatment success rate (AOR=2.17, CI=1.32-3.57) than retreated cases including relapse, failures, defaulters, transferred in cases. Whereas, HIV positive tuberculosis patients had significantly lower treatment success rate (AOR= 0.43, CI=0.28-0.65) than HIV negative ones (Table 4).

Characteristics	Frequency	Treatment success		COR	95% CI	P-Value	A OR *	95% CI	P-value
		Yes N (%)	No N (%)						
Sex									
Male	544 (59.6)	413 (75.9)	131 (24.1)	-----	----	--	1	-----	
Female	372 (40.4)	303 (81.5)	69 (21.8)	1.4	1.04-1.93	0.05	1.23	1.10-1.75	0.05

HIV Sero Status(711)									
HIV Positive	158 (22.2)	106 (67.1)	52 (32.9)	0.48	0.33-0.72	0.05	0.43	0.28-0.65	<0.001
HIV Negative	553 (77.8)	447 (80.8)	106 (19.2)	1	-----	-----	1	-----	---
Patient Category									
New	808	645 (79.8)	163 (20.2)	2.06	1.34-3.18	0.001	2.17	1.32-3.57	0.002
Retreated	108	71 (65.7)	37 (34.3)	1	-----	-----	1	-----	----
Age Group (years)									
0-14	101 (11.0)	91 (90.1)	10 (9.9)	4.55	1.79-11.56	0.02	4.99	1.75-14.27	0.003
15-24	296 (32.3)	229 (77.4)	67 (22.6)	1.71	0.83- 3.51	0.14	1.95	0.87-4.36	0.1
25-34	253 (27.6)	196 (77.5)	57 (22.5)	1.72	0.83-3.56	0.14	2.52	1.10-8.91	0.029
35-44	124 (13.5)	99 (79.8)	25 (20.2)	1.98	0.89-4.40	0.09	3.5	1.37-8.91	0.009
45-54	64 (7.0)	50 (78.1)	14 (21.9)	1.79	0.73-4.35	0.2	2.22	0.81-6.06	0.121
55-64	39 (4.3)	25 (64.1)	14 (35.9)	0.89	0.35-2.27	0.81	0.92	0.31-2.73	0.881
≥ 65	39 (4.3)	26 (66.7)	13 (33.3)	1	----	----	1	----	----

Table 4: Crude and Adjusted odds ratios for various factors that might affect treatment outcomes among tuberculosis patients, Bale Robe Hospital, September 2007-August 2012, N=916, TB=Tuberculosis, OR=Odds Ratio, CI=Confidence Interval, N=Number, *=All the variables in the table are included in the model.

Of the total 916 registered patients in the cohort, 834 (91%) survived, while 82(9%) were died in the entire follow-up period. In this study, the proportion of death from pulmonary negatives, pulmonary positives and extra pulmonary TB patients were 13.1 %, 6.7 and 5.6%, respectively.

Participants' HIV sero-status, tuberculosis type, and age, were significantly associated with patients' death (p<0.05). In multivariate

logistic regression older ones (age ≥ 65) were more likely to die than the younger groups (AOR=5.50, CI=1.21-25.01). HIV positive tuberculosis patients were four times more likely to die than HIV negative TB patients (AOR=4.32, CI=2.45-7.64). In addition, smear negative pulmonary tuberculosis patients were two times more likely to die than smear positive and extra pulmonary tuberculosis patients (AOR=2.56, CI=1.44-4.55, AOR=2.00, CI=1.05-3.84) Table 5.

Characteristics	Death Status		Crude OR	95% CI	P-Value	Adjusted OR *	95% CI	P-Value
	Alive N (%)	Died N (%)						
HIV Status								
HIV Positive	127 (80.4)	31 (19.6)	3.85	2.27-6.52	0	4.32	2.45-7.64	<0.001
HIV Negative	520 (94.4)	33 (6.0)	1	----	---	1		
TB Types								
SPPTB	222 (93.3)	16 (6.7)	1.22	0.60-2.47	0.58	1.17	0.52-2.57	0.72
SNPTB	324 (86.9)	49 (13.1)	2.56	1.44-4.55	0	2	1.05-3.84	0.05
EPTB	288 (94.4)	17 (5.6)	1	-----	---	1	---	----
Age Group (years)								
≤ 14	97 (96)	4 (4.0)	1	----	----	1	---	--
15-24	277 (93.6)	19 (6.4)	1.66	0.55-5.01	0.36	2.04	0.56-7.39	0.28
25-34	232 (91.7)	21 (8.3)	2.2	0.73-6.56	0.59	1.5	0.41-5.54	0.55
35-44	110 (88.2)	14 (11.3)	3.09	0.98-9.70	0.05	1.31	0.32-5.35	0.71

45-54	54 (84.4)	10 (15.5)	4.5	1.34-15.00	0.01	3.53	0.86-14.50	0.08
55-64	32 (82.1)	7 (17.9)	1.46	1,46-19.31	0.01	4.5	0.95-21.28	0.06
≥65	32 (82.1)	7 (17.9)	1.46	1,46-19.31	0.01	5.5	1.21-25.01	0.03

Table 5: Crude and Adjusted odds ratios for various factors that might affect, Death rate among tuberculosis patients, Bale Robe Hospital, 2007-2012, N=916, TB=Tuberculosis, OR=Odds Ratio, CI=Confidence Interval, N=Number, AOR= adjusted OR. * =All variables showed significant association in the bivariate analysis are included in the model.

Discussion

According to the WHO 2013 report on global tuberculosis control [2], the treatment success rates under the DOTS programs among 22 high-burden countries (HBCs) varied from 65% in Russian Federation to 95% in China, with an average of 88%. In the same year, the global treatment success rate was 87% among all new TB cases. Of the 22 HBCs, 15 reached or exceeded a treatment success rate of 85% among all new cases in 2011, including Ethiopia, following a major improvement from 77% in 2010 to 89% in 2011 [2].

In agreement with previous study conducted in Gonder, Ethiopia [15] and in Italy [22], in this study, larger proportion of male patients (59.6%) than female patients (40.4%) and lower proportion of patients older than 55 years of age (8.6%), registered for TB treatment, but this finding is in contrary to a study done by Beza in the same region [16].

More than half (59.9%) of the study participants were concentrated between the age group of 15-34 years, which is believed to be the productive segment of the society. This is in agreement with a study done in South Ethiopia [9] and Addis Ababa [13]. This indicates the negative impact of TB on the socio-economic condition of the society.

Studies conducted in different parts of Ethiopia documented different rate of treatment success rates ranging from 29.5% in Gondar, North west Ethiopia [15], to 89.2% in Tigray, Northern Ethiopia [17]. In our study, the overall treatment success rate was 78.2% among a cohort of tuberculosis patients registered for DOTs in Bale Robe Hospital between 2007 to 2012, which is lower than the NTLCP and WHO target of 85%. In our study treatment success rate among all new TB patients was found to be 78.9%. Treatment success rate of 78.2% of the study is in agreement with the previous study conducted in South Ethiopia [9] and much better than that of a study conducted in Gondar which is 29% [15], in Gambella 63.4% [23], and in South Ethiopia 73% [8], low income areas of Italy 56.5% [22] and Europe 74.4% [24]. However, TSR of 78.2% is slightly lower than most studies done in different parts of Ethiopia which is ranging from 80.5% in Gonder [7] to 89.2% in Tigray Region [17].

In agreement with several local studies, being female, younger in age and HIV-negative TB patients more likely result in good treatment outcome than their counter part [7-9,11,15,17,25,26]

In the present study, HIV sero-status of 711 (77.6%) of study participants was determined, out of which 158 (22.2%) of were found to be HIV sero-positive. Treatment outcomes are worse among HIV-positive TB patients compared with HIV-negative TB patients. In 2011, the TSR for all new HIV-positive TB patients was 73% compared with 87% among HIV negative TB patients (2). In this study, treatment success rate among HIV negative TB patients was 80.8 % compared with 67.1% among HIV positive ones.

In the current study, from the total of 200 (21.8%) TB patients with a poor treatment outcome, the largest proportion (41%) was caused by death followed by defaulters (27.5%) and transferred out (27%). The overall death rates of TB patients in this study was found to be 82 (9%), which is greater than 3.3 % in Northwest Ethiopia [25], 3.7% in a study done in Addis Ababa [12], 3.6% in Gambella [20] and 2.6% in Southern Ethiopia [8] but slightly lower than a study conducted in Gondar University Hospital [15] with death rate of 10.1%.

It is evident that, as the age of the study subjects advanced, the death rate of patients was steadily increased from 4% in the age group of ≤ 14 years to 17.9% in the age group of ≥ 55 years (Table 2). This is in agreement with the finding of a study done in Gonder and Addis Ababa [13,15]. Older age ≥ 65 years has been found to be an independent factor to determine death, due to increasing co morbidities as well as the general immunological deterioration with age [15].

In agreement with previous studies done in different part of the world, in the present study, older ages, smear negative [12,15] and HIV positive [7,10] pulmonary TB patients were more likely to die than their counter parts.

Conclusion

Being female, younger age and HIV negative were predictor variables for treatment success of TB patients. Although the treatment success rate is fairly good, a high proportion of patients death (9%) and 22.2% of HIV prevalence among TB patients is a serious public health concern that needs to be addressed urgently in the area.

Authors Contribution

BT: Conceived, designed the project and collected the data, and reviewed the manuscript.

ET: Developed the proposal, analyzed, interpreted the data and prepared the manuscript for publication.

Begna T: Designed the project, collected the data and reviewed the manuscript. All of these authors provided critical comments for revision and approved the final version of the manuscript.

GA: Developed the proposal, analyzed, interpreted the data and prepared the manuscript for publication.

Acknowledgement

We are very grateful for the TB clinic staff of the study site, and Addis Ababa University for financial support.

References

1. Woldeyohannes D, Kebede N, Erku W, Tadesse Z (2011) Ten years' experience of directly observed treatment short-course (dots) therapy for tuberculosis in Addis Ababa, Ethiopia. *Ethiop Med J* 49: 221-229.
2. WHO: Global tuberculosis report 2013. WHO Report 2013 Geneva 2013.
3. FMOH: Guidelines for Clinical and Programmatic Management of TB, TB/HIV and Leprosy In Ethiopia, Addis Ababa, Ethiopia 2013.
4. Tiemersma EW (2011) Natural history of tuberculosis: Duration and fatality of pulmonary tuberculosis in HIV negative patients: A systematic review. *PLoS ONE* 6.
5. Robert M, Jasmer CBS, Leah C Gonzalez, L Masae Kawamura, Dennis H Osmond, et al. (2004) Tuberculosis treatment outcomes directly observed therapy compared with self-administered therapy. *Am J Respir Crit Care Med* 170: 6.
6. Faustini A, Hall AJ, Perucci CA (2005) Tuberculosis treatment outcomes in Europe: A systematic review. *Eur Respir J* 26: 503-510.
7. Zelalem Addis WB, Alemu A, Mulu A, Ayal G, Negash H (2013) Treatment outcome of tuberculosis patients in Azezo Health Center, North West Ethiopia. *Int J Biomed Adv Res* 4: 7.
8. Shargie EB, Lindtjorn B (2005) DOTS improves treatment outcomes and service coverage for tuberculosis in South Ethiopia: A retrospective trend analysis. *BMC Public Health* 5: 62.
9. Munoz-Sellart M, Cuevas LE, Tumato M, Merid Y, Yassin MA (2010) Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. *Int J Tuberc Lung Dis* 14: 973-979.
10. Sileshi Balewgizie ND, Belaineh Girma, Muluken Melese, Pedro Suarez (2013) Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: A retrospective cohort study. *BMC Infect Dis* 13: 10.
11. Nigatu T, Abraha M (2010) Epidemiological analysis of tuberculosis trends in Ethiopia: 2000-2009. *Tuberk Toraks* 58: 375-384.
12. Getahun B, Ameni G, Biadgilign S, Medhin G (2011) Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. *BMC Infect Dis* 11: 127.
13. Getahun B, Ameni G, Medhin G, Biadgilign S (2013) Treatment outcome of tuberculosis patients under directly observed treatment in Addis Ababa, Ethiopia. *Braz J Infect Dis* 17: 521-528.
14. Datiko DG, Lindtjorn B (2009) Tuberculosis recurrence in smear-positive patients cured under DOTS in southern Ethiopia: Retrospective cohort study. *BMC PUBLIC health* 9: 348.
15. Tessema B, Muche A, Bekele A, Reissig D, Emmrich F, et al. (2009) Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five year retrospective study. *BMC Public Health* 9: 371.
16. Beza MGMTW, Teferi MD, Getahun YS, Bogale SM, Tefera ASB (2013) Five years tuberculosis treatment outcome at Kolla Diba Health Center, Dembia District, Northwest Ethiopia: A retrospective cross-sectional analysis. *J Infect Dis Ther* 1: 6.
17. Berhe G, Enqueselassie F, Aseffa A (2012) Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray region, Northern Ethiopia. *BMC Public Health* 12: 537.
18. Munoz-Sellart M, Yassin MA, Tumato M, Merid Y, Cuevas LE (2009) Treatment outcome in children with tuberculosis in southern Ethiopia. *Scand J Infect Dis* 41: 450-455.
19. Nigatu T, Abraha M (2010) Epidemiological analysis of tuberculosis trends in Ethiopia: 2000-2009. *Tuberk Toraks* 58: 375-384.
20. Demeke D, Legesse M, Bati J (2013) Trend of tuberculosis and treatment outcomes in Gambella region with special emphasize on Gambella Regional Hospital, Western Ethiopia. *J Mycobac Dis* 3: 8.
21. FMOH: Tuberculosis, Leprosy and TB/HIV prevention and Control program manual. Manual 2008, 4th ed.
22. Baussano I, Pivetta E, Vizzini L, Abbona F, Bugiani M (2008) Predicting tuberculosis treatment outcome in a low-incidence area. *Int J Tuberc Lung Dis* 12: 1441-1448.
23. Demeke D, Legesse M, Bati J (2013) Trend of tuberculosis and treatment outcomes in Gambella region with special emphasize on Gambella Regional Hospital, Western Ethiopia. *J Mycobac Dis* 3: 1-8.
24. Faustini A, Hall AJ, Perucci CA (2005) Tuberculosis treatment outcomes in Europe: A systematic review. *Eur Respir J* 26: 503-510.
25. Beza MG WM, Teferi MD, Getahun YS, Bogale SM, et al. (2013) A five years tuberculosis treatment outcome at Kolla Diba Health Center, Dembia District, Northwest Ethiopia: A retrospective cross-sectional analysis. *Infect Dis Ther* 1: 6.
26. Demeke D LM, Bati J (2013) Trend of tuberculosis and treatment outcomes in Gambella region with special emphasize on Gambella Regional Hospital, Western Ethiopia. *J Mycobac Dis* 3.